Preliminary results have been reported by Inovio Pharmaceuticals from an early-stage trial of the COVID-19 vaccine candidate INO-4800 in a cohort of 40 healthy adults. Data showed 94% of 36 eligible participants registered immunological responses, and a Phase II/III study is planned for this summer.
94% response rate reported for COVID-19 vaccine candidate
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.